✦ LIBER ✦

A model of MPTP-induced Parkinson's disease in the goldfish

✍ Scribed by Weinreb, Orly; Youdim, Moussa B H

Book ID: 109946329
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 329 KB
Volume: 2
Category: Article
ISSN: 1750-2799
DOI: 10.1038/nprot.2007.393

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neurochemical findings in the MPTP model

Neurochemical findings in the MPTP model of Parkinson's disease

✍ N. Schmidt; B. Ferger 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 300 KB

Protocol for the MPTP mouse model of Par

Protocol for the MPTP mouse model of Parkinson's disease

✍ Jackson-Lewis, Vernice; Przedborski, Serge 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 295 KB

Topiramate reduces levodopa-induced dysk

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

✍ Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic actio

Effects of classical and novel agents in

Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease

✍ S. P. Close; P. J. Elliott; A. G. Hayes; A. S. Marriott 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 622 KB

Classic toxin-induced animal models of P

Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP

✍ Andreas Schober 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 693 KB

Neuroprotective effects of (±)-kavain in

Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease

✍ Nicole Schmidt; Boris Ferger 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o